Zobrazeno 101 - 110
of 15 664
pro vyhledávání: ''
Autor:
Frances B. Maguire, Qian Li, Elysia Alvarez, Justine M. Kahn, Renata Abrahão, Jamie E. Flerlage, Theresa H.M. Keegan
Publikováno v:
Cancer
Cancer, vol 127, iss 24
Cancer, vol 127, iss 24
BackgroundHodgkin lymphoma (HL) is a treatable tumor affecting children, adolescents and young adults (AYAs; 15-39 years old). Population-based studies report worse survival for non-White children and AYAs but have limited data on individual therapeu
Publikováno v:
Hematological Oncology. 39:664-673
Peripheral T-cell lymphomas (PTCLs) are known to have an aggressive clinical course and grave prognosis. Several recommended first-line treatment regimens are available, but identification of the superior treatment remain elusive. We conducted a syst
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Shusuke Akamatsu, Hideaki Takada, Ryoichi Saito, Takayuki Goto, Akihiro Hamada, Toru Sakatani, Takeshi Sano, Yuki Kita, Kei Mizuno, Keiyu Matsumoto, Osamu Ogawa, Kenji Nakamura, Takashi Kobayashi, Tatsuaki Tsuruyama, Kaoru Murakami
Publikováno v:
Cancer Science
Overcoming cisplatin (CDDP) resistance is a major issue in urothelial cancer (UC), in which CDDP‐based chemotherapy is the first‐line treatment. WEE1, a G2/M checkpoint kinase, confers chemoresistance in response to genotoxic agents. However, the
Publikováno v:
Thoracic Cancer, Vol 12, Iss 19, Pp 2551-2563 (2021)
Thoracic Cancer
Thoracic Cancer
Background Recent studies have found that programmed death ligand 1 (PD‐L1) might be involved in chemotherapy resistance in non‐small cell lung cancer (NSCLC). Arsenic sulfide (As4S4) has been recognized to have antitumor activities and enhance t
Publikováno v:
The Prostate. 81:1225-1234
Objective The aim of present study was to determine and compare the overall response rates, progression-free survival (PFS), overall survival (OS), and clinical toxicity of the combination of 177Lu-PSMA-617 radioligand therapy (PRLT) and abiraterone
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 6022-6034 (2021)
Cancer Medicine
Cancer Medicine
Background Chemotherapy is an important treatment for lung cancer. The molecular mechanism of lung adenocarcinoma (LUAD) chemoresistance is not completely understood. Methods Weighted gene co‐expression network analysis (WGCNA) was applied to scree
Autor:
Keisuke Shigeta, Hiroaki Kobayashi, Mototsugu Oya, Takayuki Takahashi, Kunimitsu Kanai, Kyohei Hakozaki, Ryuichi Mizuno, Koichiro Ogihara, Yuta Umezawa, Koshiro Nishimoto, Takahiro Maeda, Shunsuke Yoshimine, Mizuki Izawa, Hiroki Ide, Eiji Kikuchi, Tetsushi Murakami
Publikováno v:
BJUI Compass, Vol 2, Iss 5, Pp 322-330 (2021)
Objective To investigate whether dose reductions in cisplatin due to renal dysfunction were associated with worse clinical outcomes in metastatic urothelial carcinoma (UC) patients. Patients and methods One hundred and fifty one metastatic UC patient
Autor:
Stéphane Oudard, Brigitte Laguerre, Carole Helissey, Mathilde Cancel, Diego Teyssonneau, Pierre Emmanuel Brachet, Edouard Auclin, Constance Thibault, Philippe Barthélémy, Johanna Noel, Cedric Pobel, Denis Maillet, Elouen Boughalem
Publikováno v:
Cancer Medicine, Vol 10, Iss 18, Pp 6304-6309 (2021)
Cancer Medicine
Cancer Medicine
Introduction Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration‐resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it.
Autor:
Rosario García-Campelo, Magdalena Arnal, Virginia Calvo, Víctor González‐Rumayor, Eloisa Jantus-Lewintre, Estela Sánchez-Herrero, Noemi Reguart, Sandra Sanz-Moreno, Carlos Camps, Atocha Romero, Dietmar Fernández‐Orth, Mariano Provencio, Bartomeu Massuti, Roberto Serna-Blasco, Vadym Ivanchuk, Manuel Dómine Gomez, Silvia Calabuig-Fariñas, Jose Miguel Sanchez
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2363-2376 (2021)
Molecular Oncology
Molecular Oncology
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utilit